The commencement of DReAMzz de-risks the Phase III pathway and signals operational execution capability. Monitor for patient dosing updates and any future Phase III data readouts. The Fast Track designation and positive Phase II data support a favorable regulatory trajectory, but the company remains pre-revenue with no disclosed cash runway — watch for potential capital raises as development progresses.
Price Chart
Executive Summary
Incannex Healthcare announced the commencement of its DReAMzz clinical study for IHL-42X in obstructive sleep apnea, a crossover dose-optimization trial designed to de-risk and refine the Phase III pathway. The company has completed site identification (14 sites), drug product manufacturing, import/export permits, and onboarded a distribution partner. IHL-42X previously received FDA Fast Track designation and showed positive Phase II RePOSA data.
Key Facts
- DReAMzz study officially commenced for IHL-42X in obstructive sleep apnea
- 14 clinical trial sites identified, drug product manufactured, import/export permits secured
- Newly appointed global distribution partner onboarded
- IHL-42X previously granted FDA Fast Track designation
- Phase II RePOSA trial showed statistically significant reductions in AHI and improvements in oxygenation and sleep quality
- Study designed as crossover dose optimization to strengthen Phase III design before commencement
Financial Impact
No financial figures disclosed; clinical-stage company with no revenue from IHL-42X
Risk Factors
- Clinical-stage company with no approved products or revenue from IHL-42X
- DReAMzz is a dose-optimization study; Phase III results remain uncertain
- No disclosed cash runway or financing details — potential dilution risk
- Obstructive sleep apnea market has established competitors (CPAP, Inspire, oral appliances)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295162 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $3.23 $3.18 | ▼ −1.55% | ▼ −3.49% | $2.62 (−18.89%) |
Aug 25, 2026 9w ago | 8-K | $3.75 $3.45 | ▼ −8.13% | ▼ −9.11% | $2.62 (−30.13%) |
Aug 11, 2026 11w ago | 8-K | $3.20 $3.23 | ▲ +0.94% | ▲ +2.00% | $2.62 (−18.13%) |
Jul 23, 2026 13w ago | Press Release | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.62 (−17.09%) |
Jul 23, 2026 13w ago | 8-K | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.62 (−17.09%) |
Jun 10, 2026 19w ago | Press Release | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.62 (−32.99%) |
Jun 10, 2026 19w ago | 8-K | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.62 (−32.99%) |
Jun 9, 2026 20w ago | 8-K | $3.67 $3.71 | ▲ +1.09% | ▼ −0.36% | $2.62 (−28.61%) |
May 14, 2026 23w ago | Press Release | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.62 (−32.47%) |
May 14, 2026 23w ago | 8-K | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.62 (−32.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers